Agenus (NASDAQ:AGEN) Downgraded by Wall Street Zen to “Hold”

Agenus (NASDAQ:AGEN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Agenus presently has a consensus rating of “Hold” and an average target price of $14.50.

Agenus Stock Down 1.5%

NASDAQ AGEN opened at $3.39 on Friday. Agenus has a 52 week low of $1.38 and a 52 week high of $7.34. The company has a 50 day moving average price of $3.21 and a 200 day moving average price of $3.73. The firm has a market cap of $130.17 million, a PE ratio of -7.37 and a beta of 1.57.

Agenus (NASDAQ:AGEN) last announced its earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.83. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. The company had revenue of $34.20 million during the quarter, compared to the consensus estimate of $28.10 million. On average, equities research analysts anticipate that Agenus will post -12.55 earnings per share for the current fiscal year.

Institutional Trading of Agenus

Several large investors have recently bought and sold shares of AGEN. Invesco Ltd. purchased a new position in shares of Agenus in the first quarter worth $88,000. AQR Capital Management LLC increased its position in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 427,604 shares during the period. Acadian Asset Management LLC purchased a new position in Agenus in the 1st quarter worth $58,000. JPMorgan Chase & Co. lifted its position in Agenus by 608.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 78,637 shares of the biotechnology company’s stock worth $359,000 after acquiring an additional 67,530 shares during the period. Finally, XTX Topco Ltd purchased a new stake in Agenus during the 2nd quarter valued at about $272,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.